Bright Minds Biosciences Inc (DRUG) - Total Liabilities
Based on the latest financial reports, Bright Minds Biosciences Inc (DRUG) has total liabilities worth $1.60 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Bright Minds Biosciences Inc to assess how effectively this company generates cash.
Bright Minds Biosciences Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Bright Minds Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Check DRUG asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Bright Minds Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Bright Minds Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CytomX Therapeutics Inc
NASDAQ:CTMX
|
USA | $50.87 Million |
|
NioCorp Developments Ltd. Common Stock
NASDAQ:NB
|
USA | $39.97 Million |
|
Shenzhen Xfh Technology Co Ltd
SHE:300890
|
China | CN¥2.65 Billion |
|
Xingtong Shipping Co. Ltd.
SHG:603209
|
China | CN¥1.89 Billion |
|
Mah Sing Group Bhd
KLSE:8583
|
Malaysia | RM3.59 Billion |
|
Ceepower Co Ltd
SHE:300062
|
China | CN¥1.71 Billion |
|
Thai Vegetable Oil Public Company Limited
BK:TVO-R
|
Thailand | ฿3.59 Billion |
|
Sella Real Estate
TA:SLARL
|
Israel | ILA3.40 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Bright Minds Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Bright Minds Biosciences Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 57.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bright Minds Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bright Minds Biosciences Inc (2019–2025)
The table below shows the annual total liabilities of Bright Minds Biosciences Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $2.38 Million | +318.23% |
| 2024-09-30 | $568.26K | +102.33% |
| 2023-09-30 | $280.86K | -81.82% |
| 2022-09-30 | $1.54 Million | +141.86% |
| 2021-09-30 | $638.57K | +323.11% |
| 2020-09-30 | $150.92K | +311.14% |
| 2019-09-30 | $36.71K | -- |
About Bright Minds Biosciences Inc
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials… Read more